Crystalline compound

JP7583851B2Active Publication Date: 2024-11-14OTSUKA AMERICA PHARMACEUTICAL INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023036730
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2015-06-17
Filing Date
2023-03-09
Publication Date
2024-11-14
Estimated Expiration
2036-06-17

AI Technical Summary

Technical Problem

Active pharmaceutical ingredients like (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane exist in various physical forms with differing processability, stability, solubility, and bioavailability, making it challenging to predict and utilize their advantageous polymorphs in pharmaceutical compositions.

Method used

The discovery and characterization of specific polymorphic forms, such as crystalline Form A and B of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride, which have distinct stability and solubility properties, enabling their use in galenic preparations.

Benefits of technology

These crystalline forms enhance the stability and solubility of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, improving the effectiveness of pharmaceutical compositions by addressing variability in physical forms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007583851000041
    Figure 0007583851000041
  • Figure 0007583851000042
    Figure 0007583851000042
  • Figure 0007583851000043
    Figure 0007583851000043
Patent Text Reader

Abstract

Generating and identifying advantageous physical forms of active pharmaceutical ingredients (e.g., free base or salt in solid, liquid, crystalline, hydrated, solvated, or amorphous form). [Solution] Crystalline Form A of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride is provided, which belongs to the P212121 space group and has the following unit cell parameters: a = 5.7779(2) Å, b = 8.6633(2) Å, c = 25.7280(8) Å, α = β = γ = 90°.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters

    US20140206740A1